Trial · NCT05834348
Results by group233
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 233
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving osimertinib: mToT | 11 | 95% Confidence Interval 10.1 to NA | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving osimertinib: mTToT | 14 | 95% Confidence Interval 11.1 to NA | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving other TKI: mToT | 9.4 | 95% Confidence Interval 8.2 to 11.2 | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving other TKI: mTToT | 15.8 | 95% Confidence Interval 13.7 to 18.1 | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ALK+ participants receiving alectinib: mToT | 20 | 95% Confidence Interval 14.7 to 23.7 | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ALK+ participants receiving alectinib: mTToT | 28 | 95% Confidence Interval 18 to NA | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ALK+ participants receiving brigatinib: mToT | 11 | 95% Confidence Interval 4.7 to NA | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ALK+ participants receiving brigatinib: mTToT | 16 | 95% Confidence Interval 11.1 to NA | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ALK+ participants receiving crizotinib: mToT | 7 | 95% Confidence Interval 2.9 to 21.6 | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ALK+ participants receiving crizotinib: mTToT | 19 | 95% Confidence Interval 10.5 to 37.0 | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ROS1+ participants receiving crizotinib: mToT | 5 | 95% Confidence Interval 2.4 to NA | Months |
| Duration of Treatment of Anti-cancer Drugs | Biomarker Cohort | ROS1+ participants receiving crizotinib: mTToT | 18 | 95% Confidence Interval 4.9 to NA | Months |
| Duration of Treatment of Anti-cancer Drugs | Non-biomarker Cohort | Non-biomarker participants receiving crizotinib: mToT | 3 | 95% Confidence Interval 2.6 to 13.3 | Months |
| Duration of Treatment of Anti-cancer Drugs | Non-biomarker Cohort | Non-biomarker participants receiving crizotinib: mTToT | 8.1 | 95% Confidence Interval 5.6 to 18.8 | Months |
| Duration of Treatment of Anti-cancer Drugs | Non-biomarker Cohort | Non-biomarker participants receiving erlotinib: mToT | 0.9 | 95% Confidence Interval 0.9 to 6.5 | Months |
| Duration of Treatment of Anti-cancer Drugs | Non-biomarker Cohort | Non-biomarker participants receiving erlotinib: mTToT | 6.3 | 95% Confidence Interval 3.7 to 26.7 | Months |
| Number of Participants Classified According to Treatments of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving osimertinib in first line | 104 | Participants | |
| Number of Participants Classified According to Treatments of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving gefitinib in first line | 86 | Participants | |
| Number of Participants Classified According to Treatments of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving erlotinib in first line | 50 | Participants | |
| Number of Participants Classified According to Treatments of Anti-cancer Drugs | Biomarker Cohort | EGFR+ participants receiving crizotinib in first line | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05834348/results